On Demand | How to treat metastatic breast cancer in 2023 and beyond

Certifications are now available!
No available data. Please contact us via an email requesting your certification or call us to help you.

Chair: V. Kaklamanis (US), Th. Foukakis (SE)

18.00-18.30 CET (19.00-19.30 GR Time) HER2-low breast cancer: a new entity? G. Curigliano (IT)

18.30-19.00 CET (19.30- 20.00 GR Time) Management algorithm of ER-positive,

HER2-negative V. Kaklamanis (US)

19.00-19.30 CET (20.00-20.30 GR Time) Management algorithm of HER2-positive

 breast cancer E. Papadimitraki (UK)

19.30-20.00 CET (20.30- 21.00 GR Time) Management algorithm of triple negative

 breast cancer A. Matikas (SE)

20.00-20.15 CET (21.00-21.15 GR Time) Q&Α


Curigliano G.
Full Professor of Medical Oncology, Department of Oncology and Hemato-Oncology, University of Milano, Director, Division of Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milano, Italy
Foukakis T.
Associate Professor , Senior Consultant, Department of Oncology-Pathology , Karolinska Institutet, Breast Center, Karolinska University Hospital, Sweden
Kaklamanis V.
MD, DSc, Professor of Medicine, Ruth McLean Bowman Bowers, Chair in Breast Cancer Research and Treatment, A.B. Alexander Distinguished Chair in Oncology, Leader, Breast Oncology Program, UT Health San Antonio, MD Anderson Cancer Center, USA
Matikas A.
Associate Professor of oncology, Karolinska Institutet, Stockholm, Sweden
Papadimitraki E.
MD, PhD, Consultant Medical Oncologist, Breast Unit & Clinical Research Facility, University College London Hospital, UK

Technical Support is available:
- everyday 09:00-17:00
- at the day of the event 09:00-21:00
For Technical Support please contact us:
Phone: +30 210 72 40 039
Email: support@livetime.gr

Event Details